Bleeding from Bone, Anastomoses, or Deep Cavities? 3 Surgical Scenarios Where Surgiclean® MPH Outperforms Conventional Hemostasis

Introduction

Every surgeon knows the frustration: capillary oozing from a freshly dissected lymph node bed, diffuse bleeding from a rough liver surface after lobectomy, or persistent seepage from a spinal canal that defies electrocautery. While pressure, ligature, and conventional procedures remain the gold standard for major vessel control, they frequently fall short when faced with irregular surfaces, hard-to-reach anatomy, or patients with compromised coagulation.

This is where adjunctive hemostatic agents become indispensable. Surgiclean® MPH Absorbable Hemostatic Particles represent a significant advancement in the field-a plant-based, thrombin-free powder that leverages proprietary microsphere technology to deliver consistent hemostatic effect in surgery across multiple specialties.

Below, we examine the clinical evidence supporting Surgiclean® MPH in three demanding surgical areas: cardiovascular/thoracic, orthopedic, and laparoscopic procedures.

Cardiovascular and Thoracic Surgery: Managing Anastomotic Leaks and Diffuse Oozing

The Clinical Challenge

In cardiovascular and thoracic procedures, bleeding often originates from anastomotic suture lines, tumor beds after resection, or extensive lymph node dissections. These sites are problematic because traditional suturing may actually exacerbate leakage, and electrocautery risks damaging delicate structures like bronchi or esophageal tissue.

Evidence of Hemostatic Effect

Surgiclean® MPH demonstrates exceptional performance in these scenarios. Clinical data shows the blood clot strength is 2-3 times that of a physiological blood clot, providing durable sealing even under the pulsatile flow conditions in vascular anastomoses.

Specific applications with documented success:

Furthermore, the powder can be applied to the pleura (with irrigation recommended post-hemostasis to prevent chest pain) and mediastinal beds following tumor resection. For thoracic surgeons concerned about air leaks, application to the lung stump serves a dual purpose-hemostasis and reduction of alveolar air leakage.

Why this matters clinically: The ability to achieve hemostasis within 1 minute on vascular structures means reduced cross-clamp time, less intraoperative blood loss, and potentially lower transfusion requirements.

Orthopedic Surgery: Solving the Bone Surface Bleeding Dilemma

The Clinical Challenge

Bone bleeding is notoriously difficult to control. Unlike soft tissue, bone cannot be sutured or compressed effectively. Cauterization damages osteocytes and delays healing, while bone wax is non-absorbable and may interfere with fusion. Surgeons performing spine surgery, joint arthroplasty, or fracture repair frequently spend precious minutes managing persistent oozing from cancellous bone surfaces.

Evidence of Hemostatic Effect

Surgiclean® MPH's microporous structure (30.8–97μm diameter) is uniquely suited to bone surfaces. Upon contact with blood, the particles rapidly absorb water-concentrating platelets, fibrinogen, and clotting factors precisely at the bleeding site. The resulting gel-like barrier applies gentle pressure to surrounding vessels while the endogenous coagulation cascade is activated.

Documented orthopedic applications:

Spine surgery (cervical, thoracic, lumbar) : Controls bleeding from vertebral body surfaces without entering the spinal canal (product is NOT intended for intraspinal use)

Joint replacement (hip, knee) : Manages diffuse oozing from reamed surfaces and soft tissue envelopes

Limb trauma and fractures (upper/lower extremities) : Addresses both bone surface bleeding and concomitant soft tissue wounds

Bone tumor resection : Controls hemorrhage from tumor beds and surrounding muscle

Critical Note: The product is contraindicated for use within the spinal lumen. For vertebral body and posterior element surfaces, however, it provides reliable hemostasis without the foreign body reaction associated with bone wax.

Real-world feedback: South Africa's Dr. Johan reports, "Surgiclean® has great hemostatic effect" -a sentiment echoed by users managing complex orthopedic oncology cases where bleeding surfaces are extensive and conventional methods prove inadequate.

Laparoscopic and Minimally Invasive Surgery: Precision Delivery to Difficult-to-Reach Sites

The Clinical Challenge

Minimally invasive surgery presents unique hemostatic challenges. Long instruments, limited maneuverability, and poor ergonomics make it difficult to apply pressure or precisely position conventional hemostats. Furthermore, smoke from electrocautery obscures visualization, and deep pelvic or upper abdominal bleeding sites may be inaccessible with standard applicators.

Evidence of Hemostatic Effect

Surgiclean® MPH addresses these barriers through its innovative delivery system-a family of purpose-designed applicators that enable smooth, precise powder delivery through trocars and working channels.

Applicator options for MIS:

Documented laparoscopic applications:

Splenectomy: Spleen fossa and hilum

Cholecystectomy: Gallbladder bed

Minimally invasive thyroid surgery: Surgical separation wounds

Adnexal tumor resection: Tumor stripping wounds

Key advantages in MIS:

No mixing or refrigeration-ready on demand, reducing setup time

Clotting begins on contact-regardless of patient coagulation status

Repeatable application-if initial hemostasis is incomplete, simply irrigate with saline and reapply

Broad area coverage-ideal for rough surfaces and irregular anatomy

French surgeon Dr. Maxence notes: "Quality of Surgiclean® is perfect. It transformed into a gel in approximately 30 seconds…powder like Arista takes more than 40 seconds." This rapid gelation is particularly valuable in MIS, where time under pneumoperitoneum directly correlates with patient outcomes.

Safety and Quality Evidence: Beyond Hemostatic Effect

For surgeons and purchasing directors, hemostatic effect must be balanced against patient safety. Surgiclean® MPH delivers on both fronts.

Real-World Safety Data

Over 810,000 units used with no reported adverse events

100% plant-based (potato starch)-zero animal components, eliminating prion and hypersensitivity risks

Thrombin-free-no risk of acquired inhibitor formation

Regulatory Approvals

CE2460 | NMPA (China)

MDSAP (Medical Device Single Audit Program)

ISO13485 | BGMP | KGMP

Complete Biodegradation

The product hydrolyzes to maltose and glucose, ultimately metabolizing to water and carbon dioxide within 14 days. No secondary surgery for removal is required.

Special Populations

Question: Is Surgiclean® MPH suitable for patients with coagulation deficiencies?
Answer: Yes. Because the mechanism is physical (water absorption and factor concentration) rather than biochemical, hemostatic effect is independent of the patient's endogenous coagulation status.

Contraindications

Do not use in neurological surgery or ophthalmic surgery.

Conclusion: Clinical Evidence Supports Surgiclean® MPH as a Trusted Hemostatic Partner

The evidence is clear: Surgiclean® MPH delivers rapid (typically 1 minute), durable (2-3x stronger clot), and safe (100% plant-based, fully absorbable) hemostasis across cardiovascular, thoracic, orthopedic, and laparoscopic surgeries. Its innovative delivery system solves the unique challenges of minimally invasive access, while its physical mechanism of action ensures efficacy even in patients with coagulopathies.

For surgeons: Download our clinical data summary or request a free sample to evaluate Surgiclean® MPH in your next complex case.

For distributors: Contact our team today to discuss regional availability, competitive pricing, and complete regulatory support documentation. The global absorbable hemostats market is growing at 6.47% CAGR-position yourself with a product backed by real-world evidence.